Early detection of silent myocardial ischemia and cardiac dysfunction in asymptomatic individuals with increased coronary artery calcium scores

Early detection of *silent* myocardial ischemia and cardiac dysfunction in asymptomatic individuals with increased coronary artery calcium scores - EARLY-SYNERGY

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55678

Enrollment

1392

Registered

2018-07-23

Start date

2019-05-27

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic heart disease oxygen deprivation cardiac muscle

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Asymptomatic individuals with increased coronary artery calcification scores on CT (executed prior to participation in this study)

Exclusion criteria

Exclusion criteria: Known history of cardiac disease Contra-indications to cardiac MRI Pregnancy Severe comorbidity and/or life expectancy

Design outcomes

Primary

Measure	Time frame
To determine the prevalence and extent of silent myocardial ischemia by stress MRI perfusion in asymptomatic and/or unrecognized high-risk individuals with proven coronary calcification on CT (CAC >300) To determine the effect of cardiac MRI and feedback of important incidental findings on the clinical presentation of the natural course of coronary atherosclerosis (occurrence/recognition of symptoms and consequent late diagnostic testing).	—

Measure

Time frame

To determine the prevalence and extent of silent myocardial ischemia by stress MRI perfusion in asymptomatic and/or unrecognized high-risk individuals with proven coronary calcification on CT (CAC >300) To determine the effect of cardiac MRI and feedback of important incidental findings on the clinical presentation of the natural course of coronary atherosclerosis (occurrence/recognition of symptoms and consequent *late* diagnostic testing).

—

Secondary

Measure	Time frame
To determine the prevalence and extent of early detected reduced LVEF and valvular dysfunction by cardiac MRI in asymptomatic and/or unrecognized high-risk individuals. To determine the association of early detected silent myocardial ischemia, reduced LVEF and valvular dysfunction by cardiac MRI with adverse clinical outcome (presentation/perception of symptoms, medical attention seeking, major adverse cardiovascular events (MACE) and quality of life) To study the predictors of abnormal CMR parameters in data derived from CT, questionnaires and cardiac blood markers. To establish an imaging dataset to perform analysis on new imaging biomarkers.	—

Measure

Time frame

To determine the prevalence and extent of early detected reduced LVEF and valvular dysfunction by cardiac MRI in asymptomatic and/or unrecognized high-risk individuals. To determine the association of early detected silent myocardial ischemia, reduced LVEF and valvular dysfunction by cardiac MRI with adverse clinical outcome (presentation/perception of symptoms, medical attention seeking, major adverse cardiovascular events (MACE) and quality of life) To study the predictors of abnormal CMR parameters in data derived from CT, questionnaires and cardiac blood markers. To establish an imaging dataset to perform analysis on new imaging *biomarkers*.

—

Countries

Netherlands

Outcome results